Scientists track rare DNA repair diseases to learn how they progress
NCT ID NCT05484570
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study is for people with rare DNA repair disorders like Cockayne syndrome, xeroderma pigmentosum, or trichothiodystrophy. Researchers will watch how symptoms like movement and balance change over time. No treatments are given—the goal is to better understand these conditions.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
About 40 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Oct 2022
- Expected to finish
-
Dec 2026
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
Any person 6 months or older who is either diagnosed with a DNA repair disorder, or has a family member who is diagnosed with a DNA repair disorder
- Ages
-
6 months and older
- Sex
-
Anyone
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Diagnosis of Cockayne syndrome (CS), xeroderma pigmentosum (XP), or trichothiodystrophy (TTD), based on genetic testing and/or key clinical characteristics l characteristics * Has one or more of the following neurodevelopmental or neurological complications * Gross motor delay (non-ambulatory or started walking after age 18 months) * Language delay (non-verbal or started talking after 18 months) * Altered muscle tone (hypertonia, dystonia, hypotonia) * Gait difficulties, including stiff gait, short stride, frequent falls, use of orthotics, use of walker * Tremors * Microcephaly * Is a family member of an individual with the above condition * No restrictions regarding current ambulatory status * Minimum age for enrollment eligibility will be 6 months due to fragility of neonates with severe forms of DNA repair disorders and limitations of motor assessment scales in infants younger than 6 months. There will be no maximum age for enrollment eligibility. * No restrictions regarding gender, race, or ethnicity. * Voluntary written consent from the participant if adult capable of consenting or parent/guardian if minor or not capable of consenting * Written consent of Legally Authorized Representative if enrolling adult lacks capacity to consent Exclusion Criteria: * Any prior history of systemic gene or cell-based therapy * Current participation in an interventional clinical trial
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Cockayne syndrome are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
University of Minnesota- Twin Cities
RECRUITINGMinneapolis, Minnesota, 55455, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- New program aims to ease burden on families of kids with rare diseases
- Could a single DNA test solve the mystery of rare brain diseases in kids?
- Scientists study rare DNA repair diseases to unlock cancer prevention secrets
- Immunotherapy combo aims to prevent colon cancer return in High-Risk patients
- Massive leukodystrophy biobank aims to unlock disease secrets
- Childhood cancer immunotherapy trial pulled before it started